BlueStone Capital Partners Announces Investment Opinion on Zoll Medical Corporation.Business Editors Note to Editors: The following is an investment opinion issued by BlueStone bluestone, common name for the blue, crystalline heptahydrate of cupric sulfate called chalcanthite, a minor ore of copper. It also refers to a fine-grained, light to dark colored blue-gray sandstone. Capital Partners NEW YORK--(BUSINESS WIRE)--Dec. 20, 2000 BlueStone Capital Initiates Coverage on Zoll Medical Corporation With 1-1 Rating Senior Analyst Scott Baily Baily is the name of more than one person:
An analyst recommendation meaning a stock is expected to do slightly better than the market return. Notes: Exact definitions vary by brokerage, but in general this rating is better than neutral and worse than buy or strong buy. / Outperform). The intermediate price target is $58 and the long-term Long-term Three or more years. In the context of accounting, more than 1 year. long-term 1. Of or relating to a gain or loss in the value of a security that has been held over a specific length of time. Compare short-term. price target is $70 according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the analyst. Analyst's Summary -- We are initiating coverage on ZOLL Medical Corporation with a 1-1 (Outperform-Outperform) rating. We believe ZOLL is a leading developer and manufacturer of external defibrillators and defibrillation technology for the cardiac resuscitation market and is the only pure play in the industry. It has demonstrated that its market leading biphasic technology is superior to the conventional (and older) monophasic technology. Moreover, ZOLL's strategy of educating the hospital, pre-hospital, and international markets of the superiority of its biphasic technology has shown excellent progress during the past year. However, we believe that it is still early and that more upside exists. ZOLL is number two in the market. -- We believe ZOLL's leading technology will continue to drive solid revenue and EPS growth over the next several years. For fiscal (September) 2001, we estimate that revenues will grow 16% to $123.0 million, and EPS will increase 29% to $1.38, up from $106.3 million. With ZOLL's stock currently trading at $39.44, it is trading at a modest 28.6 times our fiscal 2001 EPS estimate of $1.38. In our opinion, in a relatively short time, ZOLL has established itself as one of the premier small-cap companies in the medical technology sector and will benefit from higher valuations. Our intermediate and long-term price targets are $58 and $70, respectively. BSCP BSCP Brotherhood of Sleeping Car Porters BSCP Base Subnet Communications Processor(s) BSCP Birkett Stevens Colman Partnership (UK architects) makes a market in the securities of this company. BlueStone Capital is a full service investment banking and brokerage BROKERAGE, contracts. The trade or occupation of a broker; the commissions paid to a broker for his services. firm focused on identifying investment opportunities in the emerging growth sector. BlueStone Capital assists clients in maximizing their growth by providing sophisticated investment strategies that are designed to achieve clients' strategic, operating and financial goals. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion